Each week, Clinical Trial Arena’s journalists analyse data on patent filings and grants that illustrate innovation trends in our sector. These patent signals show where the leading companies are focusing their research and development investment, and why. We uncover key innovation areas in the sector and the themes that drive them.  

This new, thematic patents coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors. 

In the past week, a few research areas have been filed for exclusive rights to market new drug candidates in these fields. Patents provide pharmaceutical companies with a 20-year market exclusivity to enable them recoup investments in drug development.

Filings for patency dipped in the following research areas from 15th to 21st June 2023: genomic, cell and gene therapies, and environment with one, zero, and zero applications filed and zero, one, and one patents granted, respectively. This brought the total number of publications to three.

At the peak, rare diseases were at six publications, five applications and one grant, showing increased research underway to help improve challenges associated with diagnosing, managing, and treating people living with rare diseases.

From 22nd to 29th June 2023, almost twice the number of publications was observed for rare diseases and gene therapy at ten and two counts, respectively. However, the number of grants remained the same, with just one grant for each. No patent was granted for the research areas- environment, genomics and Covid-19.